fr104
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02800811)
Timeline
Indications
Mechanism of action
CD28 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- fr104
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07290777 | Phase 2 | Jul 31, 2026 | Veloxis Pharmaceuticals |
| NCT05238493 | Phase 1 | Apr 26, 2022 | Veloxis Pharmaceuticals |
| NCT04837092 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2021 | OSE Immunotherapeutics, University of Nantes |
| NCT02800811 | Phase 1 | Apr 1, 2015 | OSE Immunotherapeutics, SGS Life Sciences |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OSE Immunotherapeutics | For profit | 2 | 1 | 2 | 2015 |
| Veloxis Pharmaceuticals | For profit | 2 | 2 | 2 | 2022 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2015 |
| University of Nantes | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1